Food Demand in a Post-Ozempic World

Brian E. Roe

Choices: The Magazine of Food, Farm, and Resource Issues, 2025, vol. 40, issue 1

Abstract: The global obesity epidemic may have finally met its match in a novel class of medications that include brand names such as Ozempic, Wegovy, and Zepbound (Cousin-Frankel, 2023). While initially introduced as a treatment for type-2 diabetes, patients taking glucagonlike peptide 1 (GLP-1) receptor agonists (see Text Box 1) found a discrete change in the amount and types of food they desire, including the curbing of cravings for certain less nutritious categories of foods (e.g., sweets, fried foods), which helped patients who were overweight or obese lose clinically significant amounts of weight and, with continued use, to maintain weights 15%–20% lower than premedication levels (Rubino et al., 2021, Aronne et al., 2024).

Keywords: Food Consumption/Nutrition/Food Safety; Food Security and Poverty (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://ageconsearch.umn.edu/record/349333/files/F ... oaded%20Feb%2012.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ags:aaeach:349333

DOI: 10.22004/ag.econ.349333

Access Statistics for this article

More articles in Choices: The Magazine of Food, Farm, and Resource Issues from Agricultural and Applied Economics Association Contact information at EDIRC.
Bibliographic data for series maintained by AgEcon Search ().